Page 8 - கோர் ஒன்று ஆய்வகங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lobe Sciences Ltd.: Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin Lobe or the Company ) is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the Agreement ) with Core One Labs Inc. (CSE: COOL) ( Core One Labs ) to pursue the formation of a joint venture involving the development, regulatory approval and marketing of biosynthetic psilocybin and other psychedelic compounds (the Joint Venture ). Lobe is pleased to pursue a partnership with Core One Labs, as we continue our business expansion efforts within the rapidly growing psilocybin and psychedelics space, said Philip Young, CEO of Lobe. A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.

United kingdomBritish columbiaPhilip youngPhilipj youngLobe sciences ltdCore one labs incVocan biotechnologies incBritish columbia newsfile corpCore one labsVocan biotechnologiesJoint ventureForward lookingDefinitive agreementஒன்றுபட்டது கிஂக்டம்பிரிட்டிஷ் கொலம்பியாபிலிப் இளம்